Weight Loss

The incretin receptor agonists are the most intensively studied peptides in current metabolic research, and the area with the largest body of published human trial data — which makes it unusual in this catalogue, where most compounds are characterised preclinically.

Mechanism differs by receptor count: single-receptor GLP-1 agonists, dual GIP/GLP-1 agonists, and triple agonists adding the glucagon receptor. Our comparison of retatrutide and tirzepatide covers what the phase 3 trials actually reported and why cross-trial percentages are not directly comparable.